Cite
Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes.
MLA
Liu, Jian-Jun, et al. “Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes.” Diabetes Care, vol. 46, no. 2, Feb. 2023, pp. 408–15. EBSCOhost, https://doi.org/10.2337/dc22-1611.
APA
Liu, J.-J., Liu, S., Wang, J., Pek, S. L. T., Lee, J., Gurung, R. L., Ang, K., Shao, Y. M., Tavintharan, S., Tang, W. E., Sum, C. F., & Lim, S. C. (2023). Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care, 46(2), 408–415. https://doi.org/10.2337/dc22-1611
Chicago
Liu, Jian-Jun, Sylvia Liu, Jiexun Wang, Sharon L.T. Pek, Janus Lee, Resham L. Gurung, Keven Ang, et al. 2023. “Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes.” Diabetes Care 46 (2): 408–15. doi:10.2337/dc22-1611.